MNDL Bio raises $2M Seed to build AI-powered gene optimisation platform
What's the deal? MNDL BioDealroom has a profile for this one. Try Dealroom →, an Israeli synthetic biology startup, has raised $2 million to develop its AI-powered gene optimisation platform. The company uses algorithm-based engineering to improve recombinant DNA technology — replacing conventional trial-and-error methods with computational precision.
The startup was co-founded by Steve Grun, a veteran chief executive with 25 years in business development and a stint leading foodtech firm Yofix Probiotics; Prof. Tamir Tuller, head of Tel Aviv University's Computational Systems and Synthetic Biology lab; and Eran Miller, who brings 15 years of R&D project management and a decade of business development in agri/food-tech.
Why now? Synthetic biology is increasingly attractive to investors as AI tools mature enough to tackle the field's complexity. Gene expression optimisation — getting cells to produce desired proteins efficiently — has long been a bottleneck in biotech and food-tech R&D. MNDL Bio's platform promises to cut both costs and timelines by making that process more predictable.
What could go wrong? At $2 million, MNDL Bio is still at an early stage. Translating computational gene optimisation into reliable, commercially viable results across industries — from food to pharmaceuticals — is a steep climb. The startup will need to demonstrate clear performance advantages over existing methods to attract larger follow-on funding and customers.
Competition is also fierce. Several well-funded companies already operate at the intersection of AI and synthetic biology, and MNDL Bio will need to carve out a defensible niche.
The signal: MNDL Bio's $2 million raise is a modest entry point into an increasingly crowded AI-for-biology space, but the founding team's blend of academic pedigree — via Tel Aviv University's Computational Systems and Synthetic Biology lab — and applied food-tech experience gives it a differentiated angle. Dealroom classifies MNDL Bio as "early growth," suggesting traction beyond pure research; the question is whether a platform play targeting gene expression optimisation can scale fast enough to compete with better-capitalised synthetic biology rivals already further along the commercialisation curve.
Read more: startuprise.org
